Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium ...Middle East

TAIPEI, Taiwan, Sept. 30, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today that the company will present the clinical design of the FP-045 Phase 1/2 clinical Fanconi anemia clinical study (FuschiA study) currently being initiated, at the Fanconi...

Hence then, the article about foresee pharmaceuticals to present phase 1 2 fanconi anemia clinical study design for its aldh2 activator fp 045 at the fanconi anemia research fund 2023 scientific symposium was published today ( Saturday 30/09/2023 - 11:12 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium )

Also on site :

• Anycubic Opens Deposits for Kobra X, Following Formnext Debut of Its Next-Generation Entry-Level Multicolor FDM Printer
• Numbrix 9 - December 26
• Southern Water accused of ‘failure’ after burst pipe leaves homes without running water on Christmas Day